ICER said AstraZeneca’s new blood pressure medicine Baxfendy is not cost-effective at its list price of $10,950 per year, highlighting a value-versus-price debate that is likely to influence payer uptake. The watchdog’s assessment comes amid heightened scrutiny of affordability and incremental clinical benefit. While not directly tied to oncology or immunology, the price-effect signal matters to biotech stakeholders because payers often use similar frameworks across therapeutic areas when negotiating formulary placement and utilization management. The ICER conclusion also reinforces a near-term theme for manufacturers: even with clinical adoption potential, pricing that does not align with health-economic thresholds can constrain real-world diffusion.